Results 21 to 30 of about 29,662,154 (279)
Harms and benefits fo sodium-glucose co-transporter 2 inhibitors [PDF]
Australian Prescriber, 2020 Sodium-glucose co-transporter 2 inhibitors are oral glucose-lowering drugs that increase the urinary excretion of glucose. In patients with type 2 diabetes and cardiovascular disease they reduce all-cause mortality, cardiac mortality, rates of hospitalisation for heart failure and the progression of renal disease There are adverse effects related to ...
Chesterman, Thomas, Thynne, Tilenka RJ
openaire +2 more sources
Sodium-glucose co-transporter-2 inhibitors and epicardial adiposity
European Journal of Pharmaceutical Sciences, 2023 Epicardial adipose tissue is a layer of adipocytes that physiologically surround the myocardium and play some physiologic roles in normal heart function. However, in pathologic conditions, the epicardial adipose tissue can present a potent cardiac risk factor that is capable of impairing heart function through several pathways, increasing the risk of ...
Habib Yaribeygi +4 more
openaire +2 more sources
Safety of Sodium-Glucose Co-Transporter 2 Inhibitors [PDF]
The American Journal of Cardiology, 2019 Sodium-glucose co-transporter 2 (SGLT2) inhibitors have a well-defined safety profile based on data obtained from numerous clinical trials, including cardiovascular outcomes trials (CVOTs) and postmarketing pharmacovigilance reporting. Adverse events including risk of genital mycotic infection and volume depletion-related events are consistent with the
Janet B. McGill, Savitha Subramanian
openaire +3 more sources
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk [PDF]
Diabetes Therapy, 2019 Patients with type 2 diabetes mellitus (T2DM) appear to have increased risk for fractures. In this context, the finding that canagliflozin, a sodium-glucose co-transporter-2 (SGLT) inhibitor, increased the risk for fracture compared with placebo in the Canagliflozin Cardiovascular Assessment Study (CANVAS), a large randomized controlled trial (RCT) in ...
Anastasia Erythropoulou-Kaltsidou +2 more
openaire +2 more sources
Sodium glucose co-transport 2 inhibitors for gout treatment
Discoveries, 2022 Hyperuricemia remains the most prevalent cause of gout. Gout patients present with joint inflammation and uric acid crystals deposition manifesting as tophi. The association of gout with increased risk of insulin resistance, diabetes, metabolic disorders, increased cardiometabolic risk, and kidney disease is well established.
Somagutta, Manoj Kumar Reddy +9 more
openaire +2 more sources
The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure [PDF]
Cureus, 2021 Sodium-glucose co-transporter-2 (SGLT2) inhibitors have evolved over the years, based on data from several randomized, double-blinded, placebo-controlled clinical trials. Formerly used primarily for blood sugar control in patients with diabetes, they are now used to decrease the risk of hospitalization for heart failure (HF), or of death from ...
Fadiran, Olusayo, Nwabuo, Chike
openaire +2 more sources
Short-Term Effect of Sodium Glucose Co – Transporter 2 Inhibitors on Routine Laboratory Examinations
Journal of Contemporary Medicine, 2022 Backgroundː In this study, we aimed to examine the effect of Sodium Glucose Cotransporter 2 inhibitors (SGLT-2i) on routine laboratory test results at 12 weeks of follow-up among type 2 diabetes mellitus (T2D) patients using empagliflozin and ...
Osman İnan, Enes Şahiner
doaj +1 more source
A model‐based meta analysis study of sodium glucose co‐transporter‐2 inhibitors
CPT: Pharmacometrics & Systems Pharmacology, 2023 Type 2 diabetes mellitus (T2DM) agent sodium‐glucose co‐transporter 2 (SGLT2) inhibitors show special benefits in reducing body weight and heart failure risks.
Xueting Yao +5 more
doaj +1 more source
Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection [PDF]
International Journal of Molecular Sciences, 2021 Sodium–glucose co-transporter 2 (SGLT2) inhibitors have been approved as a new class of anti-diabetic drugs for type 2 diabetes mellitus (T2DM). The SGLT2 inhibitors reduce glucose reabsorption through renal systems, thus improving glycemic control in all stages of diabetes mellitus, independent of insulin.
Victor Chien-Chia Wu +2 more
openaire +2 more sources
, 2022 The conventional conception of the therapy of heart failure (HF) with reduced ejection fraction has been recently modified by adding sodium-glucose co-transporter-2 (SGLT2) inhibitors to the combination consisting of beta blockers, mineralocorticoid ...
Alexander A. Berezin +1 more
core +1 more source